Originally, nearly 20 years ago, it was demonstrated that effective anti-myeloma CD8+ T cells—able to exert cytolytic and IFN-γ-producing responses toward autologous malignant PCs—can be generated from the PB and BM of MM patients after ex vivo stimulation with DCs pulsed with autologous tumor cell lysates, while freshly isolated T cells were not reactive against autologous MM cells [63]. The gene discussed is CD8A; the disease is Miyoshi myopathy.